Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas

Pham, Duy Khanh; Kris, Mark G.; Riely, Gregory J.; Sarkaria, Inderpal S.; McDonough, Tiffani L; Chuai, Shaokun; Venkatraman, Ennapadam; Miller, Vincent A.; Ladanyi, Marc; Pao, William; Wilson, Richard K.; Singh, Bhuvanesh; Rusch, Valerie W.

doi:10.1200/jco.2005.04.3224

Cited by 193 publications

(151 citation statements)

References 21 publications

Supporting

Mentioning

134

Contrasting

Order By: Relevance

“…There have been several reports of an inverse correlation between smoking exposure and EGFR mutation rate Pham et al, 2006;Sugio et al, 2006;Tam et al, 2006;Toyooka et al, 2006). In line with these studies, our data show that smoking status, unlike EGFR mutation status, is not an independent prognostic factor.…”

Section: Predictors Of Survival Benefits With Gefitinib M Satouchi Et Alsupporting

confidence: 86%

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib

et al. 2007

View full text Add to dashboard Cite

This study aimed to identify predictive factors associated with prognostic benefits of gefitinib. A total of 221 Japanese patients who received gefitinib (250 mg day À1 ) were examined retrospectively and potential predictive factors analysed. Overall response rate (ORR) was 24.4% and median survival time (MST) was 8.0 months. In a log-rank test, survival was significantly better in females, patients with adenocarcinoma, never-smokers, favourable performance status (PS) and patients with epidermal growth factor receptor (EGFR) mutation. The lower the smoking exposure (Brinkman Index (BI) ¼ cigarettes per day Â years smoked), the better the MST (BI 0: 14.5 months, BI o500: 9.5 months, BI 500 to o1000: 6.9 months, BI X1000: 4.0 months). Positive-EGFR mutation status and PS 0 -1 were independent predictors of favourable prognosis by multivariate analysis. Prognosis was significantly different according to EGFR mutation status (with the same smoking status), but not according to smoking status (with the same EGFR mutation status). EGFR mutation status is the most important independent predictor of survival benefit with gefitinib treatment. Although differences in prognosis were observed according to relative smoking status and smoking exposure, the results suggested that smoking is not a direct predictor of prognosis, yet is a surrogate marker of EGFR mutation status.

show abstract

Section: Predictors Of Survival Benefits With Gefitinib M Satouchi Et Alsupporting

confidence: 86%

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The reduction in statistical significance is likely owing to the loss of power associated with the overall rarity of LKB1 mutations among never or light former smokers. For these analyses we combined both never smokers and light (p10 pack years) smokers as the frequency of mutations in other oncogenes such as EGFR is similar in these two patient groups (Pham et al, 2006). There were no correlations between LKB1 mutations and gender or age of a patient.…”

Section: Association Of Lkb1 Tumour Suppressor Mutations In Nsclc Witmentioning

confidence: 99%

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients

et al. 2008

View full text Add to dashboard Cite

Somatic mutations of LKB1 tumour suppressor gene have been detected in human cancers including non-small cell lung cancer (NSCLC). The relationship between LKB1 mutations and clinicopathological characteristics and other common oncogene mutations in NSCLC is inadequately described. In this study we evaluated tumour specimens from 310 patients with NSCLC including those with adenocarcinoma, adenosquamous carcinoma, and squamous cell carcinoma histologies. Tumours were obtained from patients of US (n ¼ 143) and Korean (n ¼ 167) origin and screened for LKB1, KRAS, BRAF, and EGFR mutations using RT-PCR-based SURVEYOR-WAVE method followed by Sanger sequencing. We detected mutations in the LKB1 gene in 34 tumours (11%). LKB1 mutation frequency was higher in NSCLC tumours of US origin (17%) compared with 5% in NSCLCs of Korean origin (P ¼ 0.001). They tended to occur more commonly in adenocarcinomas (13%) than in squamous cell carcinomas (5%) (P ¼ 0.066). LKB1 mutations associated with smoking history (P ¼ 0.007) and KRAS mutations (P ¼ 0.042) were almost mutually exclusive with EGFR mutations (P ¼ 0.002). The outcome of stages I and II NSCLC patients treated with surgery alone did not significantly differ based on LKB1 mutation status. Our study provides clinical and molecular characteristics of NSCLC, which harbour LKB1 mutations.

show abstract

“…The number of packs smoked per year (more than 15 packs/year, P <0.001) and smoke-free years (smoking cessation less than 25 years ago, P <0.02) predicted the lower prevalence of EGFR mutations compared to smokers. 68 A Japanese trial examined EGFR gene mutations within exons 18-21 and their correlations to clinico-pathological factors and other genetic alterations in 154 resected tumour specimens. EGFR mutations were observed in 39%, all of which were adenocarcinomas.…”

Section: Egfr Mutations In Lung Cancer In Smokersmentioning

confidence: 99%

Tobacco Smoking and Lung Cancer : Perception Changing Facts = تدخين التبغ و سرطان الرئة : إدراك تغير الحقائق

Furrukh¹

2013

SQUMJ

View full text Add to dashboard Cite

Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas

Cited by 193 publications

References 21 publications

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients

Tobacco Smoking and Lung Cancer : Perception Changing Facts = تدخين التبغ و سرطان الرئة : إدراك تغير الحقائق

Contact Info

Product

Resources

About